Cytokinetics begins dosing omecamtiv mecarbil in Phase III cardiovascular trial
Cytokinetics has begun dosing patients in Japan in a Phase III cardiovascular outcomes clinical trial (GALACTIC-HF) of omecamtiv mecarbil as a potential heart failure treatment.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Cardiovascular | Clinical Trials | Heart | Heart Failure | Japan Health | Pharmaceuticals